AdaptHealth Corp (AHCO) Stock Price Today
NVIDIA Board launches probe into CEO Jensen Huang over foreign intelligence concerns.
NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...
Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
Lawsuit probes J.B. Hunt for allegedly misleading investors after Q3 earnings warning
Rosen Law Firm is investigating J.B. Hunt Transport Services for possibly providing misleading business information to investors after the company warned of a Q3 earnings decline. The firm's shares dropped sharply following a CNBC report about increa...
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
Cisco's 2000 peak stock price took over 25 years to surpass, highlighting risks for today's AI investors.
Cisco briefly became the world's most valuable company in March 2000, with its stock closing at $80.06. However, investors who bought at that peak had to wait over 25 years to see a higher closing price, as the dot-com crash caused an 87% drop in sha...
Sequoia partners caught off guard by Roelof Botha joining SpaceX board amid firm shakeup
Sequoia Capital recently announced major changes including closing its London office and merging teams, which some see as undoing former leader Roelof Botha's legacy. The tension escalated when Botha joined SpaceX's board without informing Sequoia pa...
Bitcoin trades just $200 above Strategy's average cost, risking losses for MSTR if BTC closes below $75,451.
Strategy Inc. holds 849,327 Bitcoin at an average cost of $75,451, with Bitcoin currently trading slightly above this level at $75,662. If Bitcoin closes below this average cost, Strategy would record significant unrealized losses impacting MSTR's fi...
JPMorgan Income ETF (JPIE) rated Buy for its strong income and controlled risk amid high inflation and rates.
The JPMorgan Income ETF (JPIE) is recommended as a Buy due to its focus on securitized assets, which currently offer better premiums than corporate bonds. The ETF is expected to provide high income with a controlled risk profile, making it a solid ch...
$1,000 invested in ADP 10 years ago grew to $4,147 with dividends reinvested, outpacing the S&P 500.
ADP's dual income from payroll fees and investing client payroll funds helped it grow steadily over the past decade. A $1,000 investment in ADP in 2016 would be worth $4,147 today with dividends reinvested, outperforming the S&P 500's 243% return. De...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.